Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
AMTAGVI drives IOVA's prospects, with a modeled $1.6B peak sales and first profit expected in 2028, yet manufacturing and adoption remain challenges. Their cash runway extends into Q3 2027, but dilution risk is material as AMTAGVI is unlikely to generate cash before then; ex-U.S. partnerships are a potential solution. The stock is upgraded to 'Hold' as recent progress is noted, but further revenue acceleration, margin improvement, and a shareholder-friendly cash solution are needed before turning bullish. Nadzeya Haroshka/iStock via Getty Images Overview My last look at Iovance Biotherapeutics, Inc. ( IOVA ), was last November. This is a company I've followed since 2018. Despite the promise of AMTAGVI (lifileucel) in unresectable or metastatic melanoma, I've become increasingly cautious in IOVA This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such p
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "outperform". They now have a $5.00 price target on the stock.MarketBeat
- Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 2/24/26 - Form 10-K
- 2/24/26 - Form 8-K
- 2/12/26 - Form 4
- IOVA's page on the SEC website